Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZ8M0K)

Drug Name

JNJ-10397049 Drug Info

Synonyms

JNJ-10397049; JNJ 10397049; 708275-58-5; UNII-1B419P24AV; CHEMBL359632; 1B419P24AV; N-(2,4-Dibromophenyl)-N'-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]-urea; JNJ10397049; SCHEMBL1818251; GTPL1701; MolPort-035-765-717; ZINC3960325; BDBM50412863; AKOS024458089; compound 9 [PMID: 15261275]; 1-(2,4-Dibromophenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-(1,3)dioxan-5-yl)urea; Urea, N-(2,4-dibromophenyl)-N'-((4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-; NCGC00379105-01; KB-77996; B5553; J3.628.691A

Indication

Disease Entry	ICD 11	Status	REF
Insomnia	7A00-7A0Z	Investigative	[1]

Cross-matching ID

PubChem CID: 9869934
CAS Number: CAS 708275-58-5
TTD Drug ID: DMZ8M0K

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Orexin receptor type 2 (HCRTR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Suvorexant	DM0E6S3	Insomnia	7A00-7A0Z	Approved	[3]
MK-3697	DM347TQ	Insomnia	7A00-7A0Z	Phase 2	[4]
MIN-202	DMZFW8V	Major depressive disorder	6A70.3	Phase 2	[5]
TAK-861	DMLGEQ7	Narcolepsy type 1	7A20.0	Phase 2	[6]
TAK-925	DM7N4H9	Narcolepsy	7A20	Phase 1	[7]
1,2-diamino cyclopentane-based derivative 25	DMEW0AT	N. A.	N. A.	Patented	[8]
1,2-diamino cyclopentane-based derivative 5	DMCP15K	N. A.	N. A.	Patented	[8]
1,2-diamino cyclopentane-based derivative 20	DM9PHIK	N. A.	N. A.	Patented	[8]
1,2-diamino cyclopentane-based derivative 15	DMBY65W	N. A.	N. A.	Patented	[8]
1,2-diamino cyclopentane-based derivative 13	DM10UX4	N. A.	N. A.	Patented	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Orexin receptor type 2 (HCRTR2)	TT9N02I	OX2R_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1701).
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 322).
3	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4	Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett. 2014 Oct 15;24(20):4884-90.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
7	Molecular mechanism of the wake-promoting agent TAK-925. Nat Commun. 2022 May 25;13(1):2902.
8	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.